GlassScriptPhysician profile
Ganesh K Akula
NPI 1154358109
$6,696.52
in general payments reported to CMS, 2019-2025
27 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $733 · 2021: $896 · 2022: $998 · 2023: $1,150 · 2024: $799 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,264 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,264.35 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,460.19 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,081.87 | 2019-2025 | Breztri, Airsupra, Symbicort |
| Boehringer Ingelheim Pharmaceuticals, INC. | $634.75 | 2019-2025 | Ofev, Jascayd, Spiriva |
| Insmed, INC. | $290.84 | 2021-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $220.39 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $220.09 | 2019-2021 | |
| Genentech USA, INC. | $210.27 | 2019-2023 | Xolair |
| Verona Pharma, INC. | $193.98 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $174.10 | 2024-2025 | Purified Cortrophin Gel |
| Janssen Biotech, INC. | $173.74 | 2021-2023 | Rybrevant |
| Novartis Pharmaceuticals Corporation | $155.82 | 2019-2023 | |
| Intuitive Surgical, INC. | $121.39 | 2022 | |
| Pfizer INC. | $120.30 | 2022-2024 | |
| Philips North America LLC | $119.66 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Electromed, INC. | $114.08 | 2019-2025 | Smartvest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $96.95 | 2019-2024 | |
| Baxter Healthcare | $71.42 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Actelion Pharmaceuticals US, INC. | $41.46 | 2022-2025 | Uptravi |
| Optinose US, INC. | $37.86 | 2021 | |
| Jazz Pharmaceuticals INC. | $28.65 | 2021 | |
| Circassia INC. | $24.79 | 2019 | |
| Vapotherm INC | $21.35 | 2023 | Vapotherm |
| Mallinckrodt Hospital Products INC. | $20.83 | 2025 | Acthar |
| Celgene Corporation | $19.54 | 2022 | |
| Inogen, INC. | $14.86 | 2024 | |
| Grifols USA, LLC | $14.68 | 2019 | |
| Daiichi Sankyo INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ganesh Akula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.